Detalhe da pesquisa
1.
Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients.
Clin Immunol
; 251: 109321, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37019421
2.
The seasonality as a relevant aspect to be considered for differential diagnosis of Trypanosoma vivax infection and co-infections in female cattle.
Comp Immunol Microbiol Infect Dis
; 109: 102180, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653007
3.
Panoramic snapshot of serum soluble mediator interplay in pregnant women with convalescent COVID-19: an exploratory study.
Front Immunol
; 14: 1176898, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37122732
4.
Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose.
Vaccine
; 41(44): 6514-6528, 2023 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37661534
5.
Serum Soluble Mediator Profiles and Networks During Acute Infection With Distinct DENV Serotypes.
Front Immunol
; 13: 892990, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35711447
6.
Phenotypic and Functional Signatures of Peripheral Blood and Spleen Compartments of Cynomolgus Macaques Infected With T. cruzi: Associations With Cardiac Histopathological Characteristics.
Front Cell Infect Microbiol
; 11: 701930, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34336723
7.
Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
Sci Rep
; 11(1): 10431, 2021 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34001945
8.
Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.
Front Immunol
; 11: 1382, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32765496
9.
Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis.
Arthritis Res Ther
; 21(1): 75, 2019 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30871593
10.
Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.
Front Immunol
; 10: 2433, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31695694
11.
Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
Front Immunol
; 10: 2192, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31616412
12.
Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.
Front Immunol
; 10: 1211, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31293563